HPV L2 Antigen Vaccine

About VaxSyna

VaxSyna is a private, pre-clinical stage biotech developing a novel vaccine platform centered on recombinant immune complexes. Its core technology fuses a human IgG antibody to target antigens, forming higher-order complexes that enhance immunogenicity. The company's early research, evidenced by multiple publications, demonstrates proof-of-concept in animal models for viruses like HSV and Zika. VaxSyna operates in the high-potential but competitive vaccine sector, focusing on creating versatile, potent, and rapidly adaptable vaccine candidates.

Therapeutic Areas

Other Human Papillomavirus infection Drugs